{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:05:17Z","timestamp":1773353117405,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s12094-017-1777-0","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T18:39:43Z","timestamp":1511203183000},"page":"84-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["SEOM clinical guideline in nasopharynx cancer (2017)"],"prefix":"10.1007","volume":"20","author":[{"given":"M.","family":"Pastor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lopez Pousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"del Barco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Perez Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Gonzalez","family":"Astorga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Castelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bonfill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Martinez Trufero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Jose","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3785-3563","authenticated-orcid":false,"given":"R.","family":"Mesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,2]]},"reference":[{"key":"1777_CR1","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http:\/\/globocan.iarc.fr . Accessed on day\/month\/year."},{"key":"1777_CR2","unstructured":"Pathology and genetics of head and neck tumors. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumours. IARC Press, Lyon 2005."},{"key":"1777_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (Head and Neck Cancers) Version 1.2017\u2014February 6, 2017."},{"key":"1777_CR4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ijrobp.2006.02.037","volume":"65","author":"XK Xeng","year":"2006","unstructured":"Xeng XK, Chen LH, Wang OS, Fu FB. Influence of (18F) fluorodeoxyglucose positron emission tomography on salvage treatment decision making for locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:1020\u20135.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1777_CR5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/hed.21174","volume":"32","author":"C Kubrak","year":"2010","unstructured":"Kubrak C, Olson K, Jha N, Jensen L, McCargar L, Seikaly H, et al. Nutrition impact symptoms: Key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment. Head Neck. 2010;32:290\u2013300.","journal-title":"Head Neck"},{"key":"1777_CR6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.prro.2011.03.003","volume":"1","author":"MP Walker","year":"2011","unstructured":"Walker MP, Wichman B, Cheng J, Coster J, Williams KB. Impact of radiotherapy dose on dentition breakdown in head and neck cancer patients. Pract Radiat Oncol. 2011;1:142\u20138.","journal-title":"Pract Radiat Oncol."},{"key":"1777_CR7","doi-asserted-by":"crossref","unstructured":"Lee AWM, Lydiatt WM, Colevas AD, et al. Nasopharynx. In: Amin MB. (Ed), AJCC Cancer Staging Manual, 8th, New York: Springer; 2017. p. 103.","DOI":"10.1007\/978-3-319-40618-3_9"},{"key":"1777_CR8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2014.02.003","volume":"110","author":"AW Lee","year":"2014","unstructured":"Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, et al. Evolution of treatment for nasopharyngeal cancer\u2013success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014;110:377\u201384.","journal-title":"Radiother Oncol."},{"key":"1777_CR9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ijrobp.2006.02.016","volume":"65","author":"DT Chua","year":"2006","unstructured":"Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys. 2006;65:1300\u20136.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"1777_CR10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","volume":"35","author":"L Ribassin-Majed","year":"2017","unstructured":"Ribassin-Majed L, Marguet S, Lee AW, Ng WT, Ma J, Chan ATC, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35(5):498\u2013505.","journal-title":"J Clin Oncol."},{"key":"1777_CR11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310\u20137.","journal-title":"J Clin Oncol."},{"key":"1777_CR12","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/jnci\/djq258","volume":"102","author":"AW Lee","year":"2010","unstructured":"Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, et al. Randomized trial of radiotherapy plus concurrent\u2013adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102:1188\u201398.","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"1777_CR13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.5732\/cjc.009.10518","volume":"29","author":"L Kong","year":"2010","unstructured":"Kong L, Chin J. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. Chin J Cancer. 2010;29(5):551\u20135.","journal-title":"Chin J Cancer."},{"key":"1777_CR14","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509\u201320.","journal-title":"Lancet Oncol."},{"key":"1777_CR15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/COC.0b013e318277d804","volume":"37","author":"C Chen","year":"2014","unstructured":"Chen C, Fee W, Chen J, Chan C, Khong B, Hara W, Goffinet D, Li D, Le QT. Salvage treatment for locally recurrent nasopharyngeal carcinoma (NPC). Am J Clin Oncol. 2014;37:327\u201331.","journal-title":"Am J Clin Oncol."},{"key":"1777_CR16","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/1097-0142(19911115)68:10<2120::AID-CNCR2820681005>3.0.CO;2-7","volume":"68","author":"R Choo","year":"1991","unstructured":"Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. Cancer. 1991;68:2120\u20134.","journal-title":"Cancer"},{"key":"1777_CR17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/1120009X.1989.11738907","volume":"1","author":"M Airoldi","year":"1989","unstructured":"Airoldi M, Pedani F, Gabriele P, Giordano C, Cavalot A, Brando V. Combined chemotherapy for recurrent and metastatic nasopharyngeal carcinoma. J Chemother. 1989;1:272\u20136.","journal-title":"J Chemother."},{"key":"1777_CR18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00000421-198808000-00002","volume":"11","author":"K Al-Kourainy","year":"1988","unstructured":"Al-Kourainy K, Crissman J, Ensley J, Kish J, Kelly J, Al-Sarraf M. Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol. 1988;11:427\u201330.","journal-title":"Am J Clin Oncol."},{"key":"1777_CR19","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388:1883\u201392.","journal-title":"Lancet"},{"issue":"Suppl 7","key":"1777_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/annonc\/mds266","volume":"23","author":"ATC Chan","year":"2012","unstructured":"Chan ATC, Gr\u00e9goire V, Lefevre J-L, Licitra L, Hui EP, Leung SF, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):83\u20135.","journal-title":"Ann Oncol."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-017-1777-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1777-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1777-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T20:20:35Z","timestamp":1719606035000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-017-1777-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1777"],"URL":"https:\/\/doi.org\/10.1007\/s12094-017-1777-0","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,2]]}}}